Why DexCom (DXCM) Is Up 16.6% After Raising 2026 Outlook And Expanding Type 2 Access
DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth
Citigroup Maintains Buy on DexCom, Raises Price Target to $88
Dexcom tweaks full-year outlook after reporting 13% growth in Q2
Why Is DexCom (DXCM) Stock Rocketing Higher Today
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90
Mizuho Maintains Outperform on DexCom, Raises Price Target to $95
JP Morgan Maintains Neutral on DexCom, Raises Price Target to $82
Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95
Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90
Stifel Maintains Buy on DexCom, Raises Price Target to $95
Benchmark Maintains Buy on DexCom, Raises Price Target to $82
Truist Securities Maintains Buy on DexCom, Raises Price Target to $93
DexCom, Inc. 2026 Q2 - Results - Earnings Call Presentation
BTIG Maintains Buy on DexCom, Raises Price Target to $90
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
DexCom (DXCM) Q2 2026 Earnings Call Transcript
DexCom, Inc. Q2 2026 Earnings Call Summary
DexCom Q2 Earnings Call Highlights
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
